A significantly greater proportion of AVP-825 patients reported headache relief at 2 hours post-dose compared with those using the placebo device ( 68 % vs 45 % , P = .002 , odds ratio 2.53 , 95 % confidence interval [ 1.45 , 4.42 ] ) .